Difference between revisions of "Triptorelin (Trelstar LA)"
m |
m |
||
| Line 7: | Line 7: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Prostate cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 6/15/2000: Initial FDA approval "in the palliative treatment of advanced [[Prostate cancer | prostate cancer]]." | ||
==References== | ==References== | ||
| Line 15: | Line 21: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Endocrine therapy]] | ||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
[[Category:GnRH agonists]] | [[Category:GnRH agonists]] | ||
| + | |||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2000]] | ||
Revision as of 16:35, 30 October 2014
Also known as Decapeptyl, Diphereline, Gonapeptyl, or Variopeptyl.
General information
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 6/15/2000: Initial FDA approval "in the palliative treatment of advanced prostate cancer."